DEF: Clover Health Investments Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals

Clover Health Investments will hold its annual stockholder meeting virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Clover Health Investments, Corp. will hold its 2025 annual meeting of stockholders on June 10, 2025, at 11:00 a.m. Eastern Time in a virtual-only format.
• Stockholders will vote on the election of Dr. Anna U. Loengard and William G. Robinson, Jr. as Class I directors, a non-binding advisory vote on executive compensation for 2024, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• Lee A. Shapiro will not stand for re-election as a Class I director.
• The record date for determining stockholders entitled to vote is April 15, 2025.
• The Board recommends voting 'FOR' the election of directors, the approval of executive compensation, and the ratification of the auditor appointment.
• Stockholders can vote online before the meeting until June 9, 2025, or during the virtual meeting.
• The company is a remote-first company and does not maintain a headquarters.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The recommendations to vote 'FOR' the proposals suggest a positive outlook from the Board's perspective.

Positives

• The company is providing a virtual meeting format, which is expected to expand access and improve communication.
• The Board is recommending 'FOR' votes on all proposals, indicating confidence in the company's direction.

Negatives

• Lee A. Shapiro will not stand for re-election as a Class I director.

Risks

• The advisory vote on executive compensation is non-binding, meaning the Board is not obligated to act in accordance with the results.
• The company's future performance is subject to various risks, as detailed in their Annual Report on Form 10-K.

Future Outlook

The company is focused on long-term value creation and aligning executive compensation with the interests of stockholders.

Management Comments

• Andrew Toy, Co-Founder and CEO, thanks stockholders for their continued support and looks forward to seeing them virtually at the Annual Meeting.
• Karen Soares, General Counsel and Corporate Secretary, emphasizes the importance of stockholders' shares being represented at the Annual Meeting.

Industry Context

The company operates in the healthcare industry, specifically focusing on Medicare Advantage plans and technology-enabled services. The proxy statement reflects standard corporate governance practices for publicly traded companies in this sector.

Comparison to Industry Standards

• The director compensation policy is designed to align the interests of outside directors with the interests of stockholders through grants of equity awards that vest over time.
• The peer group companies were chosen based on, among other things, (i) industry, including healthcare and technology companies, (ii) revenue, (iii) revenue growth, (iv) market cap, (v) market cap as a multiple of revenue, and (vi) headcount.
• The company's executive compensation program includes the following design features: a balanced mix of cash and equity, as well as appropriately balanced fixed (base salary) and variable (cash incentives and equity-based awards) compensation; a mix of short-term and long-term incentives, with short-term incentives currently representing a lower proportion of the total mix; an incentive compensation clawback policy that requires us to recoup certain incentive compensation paid to our executive officers in the event of an accounting restatement or breach of company policy or legislation; an executive minimum stock ownership policy that helps ensure that the interests of our executive officers are aligned with those of our stockholders; cash and equity incentives based on achieving Company performance objectives; caps on annual cash incentive payouts; general alignment with prevalent low-risk pay practices; policies prohibiting hedging and pledging of Clover stock by our employees, officers or directors.

Management Changes

Related Party Transactions

• The Company has various contracts with IJKG Opco LLC (d/b/a CarePoint Health Bayonne Medical Center), Hudson Hospital Opco, LLC (d/b/a CarePoint Health Christ Hospital) and Hoboken University Medical Center Opco LLC (d/b/a CarePoint Health Hoboken University Medical Center), which collectively do business as the CarePoint Health System ('CarePoint Health'), for the provision of inpatient and hospital-based outpatient services.
• We have a contract with Medical Records Exchange, LLC (formerly known as 'ChartFast,' now d/b/a Credo) pursuant to which we receive administrative services related to medical records retrieval via Credo's electronic applications and web portal platform.
• Since July 2, 2021, we have contracted with Thyme Care, Inc. ('Thyme Care'), an oncology benefit management company, through which Thyme Care was engaged to provide concierge cancer coordination services to the Company's insurance members in New Jersey and develop a provider network to help ensure member access to high-value oncology care.

Stakeholder Impact

• Stockholders are asked to vote on key proposals that will impact the company's governance and direction.
• Executive compensation decisions impact the alignment of management's interests with those of stockholders.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote their shares.
• The company will hold the annual meeting on June 10, 2025.
• The Board and management will consider the results of the votes when making future decisions.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, Ernst & Young, virtual meeting, Clover Health, governance